We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Haemonetics (HAE) Up 4.9% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Haemonetics (HAE - Free Report) . Shares have added about 4.9% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Haemonetics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Haemonetics Q1 Earnings Top Estimates, Margins Improve
Haemonetics delivered adjusted earnings per share of 50 cents in the first quarter of fiscal 2022, reflecting 8.7% year-over-year growth. The bottom line surpassed the Zacks Consensus Estimate by 6.4%.
On a GAAP basis, net loss was 9 cents per share against the year-ago earnings per share of 21 cents.
Total Revenues
Revenues increased 16.8% (up 6% on an organic basis) to $228.5 million in the first quarter of fiscal 2022. The top line also surpassed the Zacks Consensus Estimate by 1.3%.
The year-over-year increase in revenues was supported by recovery across all businesses, especially Hospital, and the initial Plasma Persona rollouts.
Revenues by Product Categories
At Plasma, revenues of $71.8 million (accounting for 31.4% of total revenues) increased 5.3% year over year (up 6.2% on an organic basis) in the reported quarter.
Revenues at Blood Center (31.9%) fell 6.2% (down 5.9% on an organic basis) to $72.9 million.
Hospital revenues (34.3%) rose 75.1% (up 26.4% on an organic basis) to $78.5 million. Under the Hospital segment, organic revenue growth in the Hemostasis Management product line was 34.3% in the first quarter of fiscal 2022 on strong capital sales in North America and EMEA.
Service revenues (2.3%) rose 10.7% (up 3.7% on an organic basis) to $5.2 million.
Margins
The company-adjusted gross margin was 54.7%, up 750 basis points (bps) year over year. The primary drivers of this improvement were the addition of Vascular Closure from the acquisition of Cardiva Medical, Inc. (Cardiva), productivity savings from the Operational Excellence Program, favorable product mix and improved operating efficiency, partially offset by the impact of previous divestitures and price adjustments.
Adjusted operating expenses in the first quarter of fiscal 2022 were $87.1 million, up 36.7% from the year-ago quarter. The increase was primarily driven by a rise in variable compensation and the acquisition of Cardiva Medical, an increase in variable compensation and continued investments.
The company-adjusted operating income was $37.9 million in the quarter under discussion, up 32.9% year over year. Adjusted operating margin was 16.6%, up 200 bps compared to the year-ago quarter.
Financial Position
Haemonetics exited the first quarter of fiscal 2022 with cash and cash equivalents of $173.5 million compared with $192.3 million at the end of fourth-quarter 2020. Long-term debt at the end of the first quarter of fiscal 2022 was $767.3 million, up from $690.6 million at the end of fourth-quarter 2021.
Cumulative net cash flow used in operating activities at the end of first-quarter fiscal 2022 was $1.7 million compared with $11.8 million net cash flow provided from operating activities a year ago.
Cumulative capital expenses (net of proceeds from sale of property, plant and equipment) incurred by the company were $13.9 million, up from the year-ago $7.7 million. It also reported free cash flow (before restructuring and turnaround costs) of $1.8 million during the same period, down 83.1% from $10.9 million a year ago.
2022 Guidance
Haemonetics has reinstated its full-year 2022 financial guidance. The company expects GAAP total revenue growth in the range of 13-18% on a reported basis (organic growth projection in the range of 8-12%). The Zacks Consensus Estimate for 2022 revenues is pegged at $1 billion.
The company expects full-year adjusted earnings per share in the band of $2.60-$3.00. The Zacks Consensus Estimate for the same is pegged at $2.78.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
At this time, Haemonetics has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions has been net zero. Notably, Haemonetics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Haemonetics (HAE) Up 4.9% Since Last Earnings Report?
It has been about a month since the last earnings report for Haemonetics (HAE - Free Report) . Shares have added about 4.9% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Haemonetics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Haemonetics Q1 Earnings Top Estimates, Margins Improve
Haemonetics delivered adjusted earnings per share of 50 cents in the first quarter of fiscal 2022, reflecting 8.7% year-over-year growth. The bottom line surpassed the Zacks Consensus Estimate by 6.4%.
On a GAAP basis, net loss was 9 cents per share against the year-ago earnings per share of 21 cents.
Total Revenues
Revenues increased 16.8% (up 6% on an organic basis) to $228.5 million in the first quarter of fiscal 2022. The top line also surpassed the Zacks Consensus Estimate by 1.3%.
The year-over-year increase in revenues was supported by recovery across all businesses, especially Hospital, and the initial Plasma Persona rollouts.
Revenues by Product Categories
At Plasma, revenues of $71.8 million (accounting for 31.4% of total revenues) increased 5.3% year over year (up 6.2% on an organic basis) in the reported quarter.
Revenues at Blood Center (31.9%) fell 6.2% (down 5.9% on an organic basis) to $72.9 million.
Hospital revenues (34.3%) rose 75.1% (up 26.4% on an organic basis) to $78.5 million. Under the Hospital segment, organic revenue growth in the Hemostasis Management product line was 34.3% in the first quarter of fiscal 2022 on strong capital sales in North America and EMEA.
Service revenues (2.3%) rose 10.7% (up 3.7% on an organic basis) to $5.2 million.
Margins
The company-adjusted gross margin was 54.7%, up 750 basis points (bps) year over year. The primary drivers of this improvement were the addition of Vascular Closure from the acquisition of Cardiva Medical, Inc. (Cardiva), productivity savings from the Operational Excellence Program, favorable product mix and improved operating efficiency, partially offset by the impact of previous divestitures and price adjustments.
Adjusted operating expenses in the first quarter of fiscal 2022 were $87.1 million, up 36.7% from the year-ago quarter. The increase was primarily driven by a rise in variable compensation and the acquisition of Cardiva Medical, an increase in variable compensation and continued investments.
The company-adjusted operating income was $37.9 million in the quarter under discussion, up 32.9% year over year. Adjusted operating margin was 16.6%, up 200 bps compared to the year-ago quarter.
Financial Position
Haemonetics exited the first quarter of fiscal 2022 with cash and cash equivalents of $173.5 million compared with $192.3 million at the end of fourth-quarter 2020. Long-term debt at the end of the first quarter of fiscal 2022 was $767.3 million, up from $690.6 million at the end of fourth-quarter 2021.
Cumulative net cash flow used in operating activities at the end of first-quarter fiscal 2022 was $1.7 million compared with $11.8 million net cash flow provided from operating activities a year ago.
Cumulative capital expenses (net of proceeds from sale of property, plant and equipment) incurred by the company were $13.9 million, up from the year-ago $7.7 million. It also reported free cash flow (before restructuring and turnaround costs) of $1.8 million during the same period, down 83.1% from $10.9 million a year ago.
2022 Guidance
Haemonetics has reinstated its full-year 2022 financial guidance. The company expects GAAP total revenue growth in the range of 13-18% on a reported basis (organic growth projection in the range of 8-12%). The Zacks Consensus Estimate for 2022 revenues is pegged at $1 billion.
The company expects full-year adjusted earnings per share in the band of $2.60-$3.00. The Zacks Consensus Estimate for the same is pegged at $2.78.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
At this time, Haemonetics has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions has been net zero. Notably, Haemonetics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.